Innovative Models for Investigation of Pathomechanisms Leading to Late Diabetic Complications

P. Nawroth

doi:10.1055/s-0032-1306299

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2012; 120(04): 177-178
DOI: 10.1055/s-0032-1306299

Editorial

Innovative Models for Investigation of Pathomechanisms Leading to Late Diabetic Complications

P. Nawroth

¹Universitätsklinikum Heidelburg, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Nawroth PP, Rudofsky G, Humpert P. Have We Understood Diabetes?. New Tasks for Diagnosis and Therapy Exp Clin Endocrinol Diabetes 2010; 118: 1-3
2 Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA_1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489
3 Riddle MC, Ambrosius WT, Brillon DJ et al. Action to Control Cardiovascular Risk in Diabetes Investigators: Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983-990
4 Wilson C. Diabetes: ACCORD: 5-year outcomes of intensive glycemic control. Nat Rev Endocrinol 2011; 7: 314
5 Fleming T, Cuny J, Nawroth G et al. Is Diabetes an acquired disorder of reactive glucose metabolites and their intermediates?. Diabetologia Jan 22 2012; [Epub ahead of print]
6 Skriver MV, Borch-Johnsen K, Lauritzen T et al. HbA_1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark. Diabetologia 2010; 53: 2328-2333
7 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
8 Gale EA. Glucose control in the UKPDS: what did we learn?. Diabet Med 2008; 25 (Suppl. 02) 9-12
9 Skyler JS, Bergenstal R, Bonow RO et al. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-192
10 Tyedmers J. Yeast as a model to understand mechanisms and consequences of protein modification by metabolism derived toxic products. Exp Clin Endocrinol Diabetes 2012; 120: 179-181
11 Teleman AA, Ratzenböck I, Oldham S. Drosphila: A model for understanding obesity and diabetic complications.. Exp Clin Endocrinol Diabetes 2012; 120: 184-185
12 Jörgens K, Hillebrands J-L, Hammes H-P et al Zebrafish: a model for understanding diabetic complications. Exp Clin Endocrinol Diabetes 2012; 120: 186-188
13 Bierhaus A, Nawroth PP. Critical evaluation of mouse models used to study pain and loss of pain perception in diabetic neuropathy.. Exp Clin Endocrinol Diabetes 2012; 120: 189-191
14 Peters V, Schmitt CP.. Murine models of diabetic nephropathy.. Exp Clin Endocrinol Diabetes 2012; 120: 192-194
15 Müller OJ, Katus HA, Backs J. Macrovascular disease in diabetes: is the mouse a suitable model?. Exp Clin Endocrinol Diabetes 2012; 120: 195-197
16 Feng Y, Busch S, Gretz N et al Crosstalk in the retinal neurovascular unit – lessons for the diabetic retina.. Exp Clin Endocrinol Diabetes 2012; 120: 200-202
17 Herzig S. Glucose effects on the peritoneum: what can we learn from rodent models?. Exp Clin Endocrinol Diabetes 2012; 120: 198-199